Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: October 5, 2007

NanoViricides Featured Story on MN1

(Nanowerk News) Everyone hates viruses. NanoViricides(OTC BB:NNVC.OB - News) has found out a way to quickly respond to both emerging viral infections as well to established viruses. Their strategy is to destroy viruses in the bloodstream after infection utilizing drugs created by their nanotechnology-based platform drug development system. Market News First (www.mn1.com) has written a feature story investigating this interesting company and its "FluCide-I and FluCide-HP treatments for influenzas."

The story is available on MN1's Web site at the following link: http://feeds.mn1.com/nanoviricides_treatments_proven_superior_in_testing_results.htm

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel NanoViricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.

About MN1.com

Market News First is an online market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.